Bridget M. Kuehn
Abstract
The FDA approved dabigatran etexilate as the first oral blood thinner for children aged 3 months to 11 years who have venous thromboembolism and received injectable blood thinners for at least 5 days. Previously, the only anticoagulant approved for children was an injectable formulation.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The FDA approved dabigatran etexilate as the first oral blood thinner for children aged 3 months to 11 years who have venous thromboembolism and received injectable blood thinners for at least 5 days. Previously, the only anticoagulant approved for children was an injectable formulation.
Key concepts: Medicine, Oral anticoagulant, Dabigatran, Venous thromboembolism, Anticoagulant, Surgery, Internal medicine, Warfarin